Judge’s ‘serious questions’ about Ackman trading in Allergan may fire SEC into action

Carly Helfand Valeant partner and leading Allergan shareholder Bill Ackman may have won the right to vote his shares at a Dec. 18 special meeting, at which he hopes to upturn Allergan's ...

Astellas sinks deeper roots into Cambridge’s hot R&D field with $1.2B pact

John Carroll Just weeks ago Astellas teamed up with Harvard's Constance Cepko on a new program for a degenerative eye disease. Today it inked a deal with Proteostasis Therapeutics ...

Novo Nordisk’s first foray into obesity comes through in Phase III

Damian Garde In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as ...

LabCorp bags Covance, diversifying into CRO biz with $6.1B buyout

John Carroll LabCorp is diversifying. The big diagnostics player has swooped in to buy the contract research organization Covance for $ 6.1 billion in cash and stock, confident that ...

PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready

Tracy Staton Since a U.S. circuit court decided the First Amendment protected a pharma sales rep from off-label marketing charges, the free-speech arguments have multiplied in cases ...

Can Gilead break into cancer? With Zydelig approval, it gets its chance

Tracy Staton Armed with a brand-new FDA approval for its blood cancer drug Zydelig (idelalisib), Gilead will take on the oncology market. FiercePharma News

AbbVie, Shire and how $54.7B can turn a ‘no’ into a ‘yes’

Damian Garde For months, AbbVie mounted a dogged pursuit of Shire, learning from the mistakes of the now-thwarted Pfizer and maintaining its patients without letting lines go cold, ...

Zogenix puts Zohydro 2.0 into high gear, aiming to beat Purdue, Teva

Tracy Staton Zogenix knows it needs to step on the gas. If the company doesn't develop an abuse-resistant version of its controversial-and-powerful painkiller Zohydro–and ...

AstraZeneca rushes immuno-oncology star into PhIII lung cancer study

John Carroll Anxious to fight off Pfizer’s $ 106 billion marriage proposal, AstraZeneca’s research team has rushed its high-profile immuno-oncology drug into a late-stage ...

Teva could jump into pharma’s deal frenzy, CEO says

Carly Helfand A few months ago, Teva CFO Eyal Desheh told the J.P. Morgan Healthcare Conference that armed with a new incoming CEO and a reasonable debt level, the Israeli company was ...

Pfizer, Novartis and 3 others put an extra $1M each into Q1 lobbying

Eric Palmer Big Pharma companies, like other corporate beings, spend millions on lobbying in Washington, DC. In fact, a handful of companies spent $ 1 million more each in the first ...

Japan’s RegImmune nails down $9.2M to get its pipeline into the clinic

Damian Garde Tokyo drug developer RegImmune has banked $ 9.2 million in Series D financing to bankroll early-stage products using the company's immune system-regulating platform. FierceBiotech ...
Page 3 of 712345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS